JP2014506890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506890A5 JP2014506890A5 JP2013554520A JP2013554520A JP2014506890A5 JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5 JP 2013554520 A JP2013554520 A JP 2013554520A JP 2013554520 A JP2013554520 A JP 2013554520A JP 2014506890 A5 JP2014506890 A5 JP 2014506890A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- use according
- methylbutyrate
- disease
- mechirubuchira
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims 1
- 230000009251 neurologic dysfunction Effects 0.000 claims 1
- 208000015015 neurological dysfunction Diseases 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443762P | 2011-02-17 | 2011-02-17 | |
| US61/443,762 | 2011-02-17 | ||
| PCT/US2012/024817 WO2012112419A1 (en) | 2011-02-17 | 2012-02-13 | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209276A Division JP6340394B2 (ja) | 2011-02-17 | 2016-10-26 | β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506890A JP2014506890A (ja) | 2014-03-20 |
| JP2014506890A5 true JP2014506890A5 (enExample) | 2015-03-26 |
| JP6034309B2 JP6034309B2 (ja) | 2016-11-30 |
Family
ID=45757211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554520A Expired - Fee Related JP6034309B2 (ja) | 2011-02-17 | 2012-02-13 | β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 |
| JP2016209276A Expired - Fee Related JP6340394B2 (ja) | 2011-02-17 | 2016-10-26 | β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209276A Expired - Fee Related JP6340394B2 (ja) | 2011-02-17 | 2016-10-26 | β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9326956B2 (enExample) |
| EP (1) | EP2675298A1 (enExample) |
| JP (2) | JP6034309B2 (enExample) |
| CN (1) | CN103347406B (enExample) |
| AR (1) | AR085297A1 (enExample) |
| BR (1) | BR112013020643A2 (enExample) |
| CA (1) | CA2825734C (enExample) |
| MX (1) | MX348708B (enExample) |
| PH (1) | PH12013501671A1 (enExample) |
| SG (1) | SG192813A1 (enExample) |
| TW (1) | TWI565420B (enExample) |
| WO (1) | WO2012112419A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2481865T3 (es) | 2010-01-29 | 2014-07-31 | Abbott Laboratories | Emulsiones nutricionales que comprenden HMB de calcio |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| PE20121730A1 (es) | 2010-01-29 | 2013-01-13 | Abbott Lab | Liquidos nutricionales envasados asepticamente que comprenden beta-hidroxi-beta-metilbutirato (hmb) |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| BR112013020643A2 (pt) | 2011-02-17 | 2016-08-02 | Abbott Lab | métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato |
| ES2421187B1 (es) * | 2012-02-23 | 2014-11-26 | Abbott Laboratories | Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato |
| EP2745708A1 (en) * | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Antidepressant effect of ß-hydroxy-ß-methylbutyrate |
| US20150351438A1 (en) * | 2013-01-29 | 2015-12-10 | Otc Nutrition Llc | Micronutrient Fortification Delivery |
| WO2014127112A1 (en) * | 2013-02-13 | 2014-08-21 | Baylor College Of Medicine | Memory enhancer and actin dynamics |
| BR112015023316A2 (pt) * | 2013-03-15 | 2017-07-18 | Abbott Lab | fórmula para bebês de baixa caloria contendo ácido beta-hidroxi-beta-metilbutírico para promover a síntese de proteína e a acreção de massa corporal magra em bebês nascidos a termo |
| WO2015148982A1 (en) | 2014-03-27 | 2015-10-01 | Winterfield Roland W | Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy |
| EP3349596B1 (en) * | 2015-09-16 | 2020-04-29 | Abbott Laboratories | Reduced fat, shelf stable liquid nutritional composition |
| BR112018009406A8 (pt) * | 2015-11-10 | 2019-02-26 | Metabolic Tech Inc | ?composição de aditivo de ração, produto de ração, método para prevenir, eliminar e/ou reduzir crescimento microbiano, e, revestimento para um produto de ração animal? |
| JP7011300B2 (ja) * | 2017-12-19 | 2022-02-10 | 株式会社島田製薬 | ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291525B1 (en) | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| US7445807B2 (en) | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| US20050027005A1 (en) | 2003-08-02 | 2005-02-03 | Matthias Boldt | Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US20060167075A1 (en) | 2005-01-25 | 2006-07-27 | Pearson James P | Modulators of FAAH |
| EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| CA2632262C (en) | 2005-12-19 | 2015-04-07 | Abbott Laboratories | Method of using .beta.-hydroxy-.beta.-methylbutyrate |
| JP5630750B2 (ja) * | 2008-03-18 | 2014-11-26 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
| EP2381784B1 (en) | 2008-12-09 | 2018-07-11 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| TW201117736A (en) | 2009-11-17 | 2011-06-01 | Hui-Chiang Lu | Compositions for sport supplement |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| PH12013501292A1 (en) | 2010-12-22 | 2019-03-22 | Abbott Lab | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
| CN103269695A (zh) | 2010-12-27 | 2013-08-28 | 雅培制药有限公司 | 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法 |
| BR112013020643A2 (pt) | 2011-02-17 | 2016-08-02 | Abbott Lab | métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato |
| HK1205692A1 (en) | 2012-03-19 | 2015-12-24 | Abbott Laboratories | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance |
| WO2014043685A1 (en) | 2012-09-17 | 2014-03-20 | Abbott Laboratories | Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof |
-
2012
- 2012-02-13 BR BR112013020643A patent/BR112013020643A2/pt not_active IP Right Cessation
- 2012-02-13 MX MX2013009528A patent/MX348708B/es active IP Right Grant
- 2012-02-13 JP JP2013554520A patent/JP6034309B2/ja not_active Expired - Fee Related
- 2012-02-13 CN CN201280009207.4A patent/CN103347406B/zh not_active Expired - Fee Related
- 2012-02-13 US US13/984,906 patent/US9326956B2/en not_active Expired - Fee Related
- 2012-02-13 EP EP12705748.7A patent/EP2675298A1/en not_active Withdrawn
- 2012-02-13 CA CA2825734A patent/CA2825734C/en not_active Expired - Fee Related
- 2012-02-13 PH PH1/2013/501671A patent/PH12013501671A1/en unknown
- 2012-02-13 SG SG2013062377A patent/SG192813A1/en unknown
- 2012-02-13 WO PCT/US2012/024817 patent/WO2012112419A1/en not_active Ceased
- 2012-02-17 TW TW101105347A patent/TWI565420B/zh not_active IP Right Cessation
- 2012-02-17 AR ARP120100566 patent/AR085297A1/es not_active Application Discontinuation
-
2016
- 2016-10-26 JP JP2016209276A patent/JP6340394B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506890A5 (enExample) | ||
| Stoodley et al. | The cerebellum and dyslexia. | |
| EP4272828A3 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| CO2019014047A2 (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios | |
| BR112015014800A2 (pt) | derivados da exendina-4 funcionalizada | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| SG10201903475TA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| PH12015500106B1 (en) | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof | |
| WO2014052935A3 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| JP2014514361A5 (enExample) | ||
| JP2014516535A5 (enExample) | ||
| JP2014507474A5 (enExample) | ||
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| BR112013005226A2 (pt) | "n-fenetiltriazolonaacetamidas substituídas e o seu uso". | |
| Isaac | Culture‐bound syndromes in mental health: A discussion paper. | |
| RU2017123243A (ru) | Состав, содержащий экстракт кожицы poria cocos, предназначенный для профилактики, облегчения состояния и лечения нейродегенеративных расстройств | |
| WO2014203188A3 (en) | Assay for complement factor i (cfi) bioactivity | |
| Maršanić et al. | Usredotočena svjesnost—Mindfulness: Primjena u djece i adolescenata. | |
| Gallup et al. | Venlafaxine-induced excessive yawning: a thermoregulatory connection. | |
| Shepherd | A play on mental illness | |
| MX2014001940A (es) | Producto farmaceutico de aerosol para administracion por inhalacion oral o nasal. | |
| BR112013006307A2 (pt) | fenilacetamidas e fenilpropanamidas substituídas e o seu uso | |
| Messinger-Rapport et al. | Clinical update on nursing home medicine: 2011 | |
| PL3085383T3 (pl) | Kompozycja farmaceutyczna zawierająca erytropoietynę i ceftriakson oraz jej wykorzystanie w wytwarzania leku do leczenia choroby parkinsona |